FTRE

Fortrea Holdings Inc.

Next est. report 2026-11-05 · BMO

MedTech Long '24: Lab Research & Trials MedTech Long '25 : US Drug Dev OutsourcingMedTech Long '25: Aging-Driven Procedures & CareMedTech Long '26: CROs

Loading…

Loading chart…

Overview

Fortrea Holdings Inc. (FTRE) is a global contract research organization (CRO) providing drug and device development services. Its Clinical Services support tria

Fortrea Holdings Inc. (FTRE) is a global contract research organization (CRO) providing drug and device development services. Its Clinical Services support trials from early to late stages, while Enabling Services offer patient access and technology solutions. Serving pharmaceutical, biotech, and medical device companies, Fortrea recently launched its AI-enabled FIT platform and is seeing strong biotech engagement, aiming for improved profitability.

What They Do (Plain English & Analogies): Fortrea Holdings Inc. is like a specialized project management and research firm for companies that are developing new medicines and medical devices. Instead of a pharmaceutical or biotech company building its own huge research department to test every new drug, they hire Fortrea to handle the complex process of clinical trials. This involves everything from designing studies and recruiting patients to collecting and analyzing data, ensuring the entire process is efficient, high-quality, and meets strict regulatory standards. They help their clients answer critical development questions, move faster, make better decisions, and reach milestones with fewer surprises.
Very Brief History: Fortrea Holdings Inc. was established in 2023 as a pure-play clinical contract research organization, following its spin-off from Labcorp. Its historical roots can be traced back through various predecessors, including Covance (from 1996 to 2021) and the Environmental Sciences Corporation, which was formed in 1968, establishing a long legacy in drug development services.
"Street Stereotype": Fortrea is generally perceived as a pure-play clinical Contract Research Organization (CRO) with significant potential for margin expansion post-spin-off. This potential is expected to be driven by aggressive cost optimization and a renewed focus on commercial execution, particularly within the biotech sector. While the company faces near-term revenue headwinds from FSP (Functional Service Provider) contract renegotiations and lower pass-through costs, the market is closely watching its ability to translate strong bookings into sustainable top-line growth. The recent launch of its AI-enabled FIT platform is viewed as a promising long-term differentiator, though its immediate financial impact and the timeline for efficiency gains to outweigh implementation costs are key areas of investor scrutiny.
Subsidiaries On Linked In*: Fortrea Argentina S.A. — Legal entity for operations in Argentina
Fortrea Australia Pty Ltd — Legal entity for operations in Australia
Fortrea Canada Inc. — Legal entity for operations in Canada
Fortrea Pharmaceutical Research & Development (Beijing) Co., Ltd. — Legal entity for operations in China
Fortrea Japan K.K. — Legal entity for operations in Japan
SnapIoT, Inc. — Technology subsidiary, acquired by predecessor
Chiltern Pesquisa Clinica Ltda. — Clinical research subsidiary, acquired by predecessor
Customer Sectors & Example Clients: Fortrea's customers primarily operate in the pharmaceutical, biotechnology, and medical device industries. The company serves a diverse client base, ranging from large pharmaceutical companies, which remain a cornerstone for Fortrea, to small and mid-sized biotech firms, including early growth innovators and publicly-listed development-stage companies. These biotech clients often focus on innovative therapeutic areas such as oncology, cardiovascular, and RNA-based therapeutics. While specific client names are not disclosed, based on its industry and global operations, Fortrea's clients would likely include major pharmaceutical companies such as Pfizer, Novartis, Merck, and Johnson & Johnson, as well as prominent biotechnology firms like Amgen, Gilead Sciences, and Regeneron, alongside numerous smaller, emerging biotechs.
New Customers / Segments They'Re Targeting: Fortrea is actively targeting and seeing encouraging growth with new and existing biotech clients. Their net new business awards are weighted towards the biotech sector, and they are experiencing increased momentum in engaging new biotech customers, which is helping to broaden and diversify their pipeline. They also continue to strengthen relationships with strategic large pharma customers.
Supply Chain And Sourcing Geographies: Fortrea maintains a global operational footprint, with a significant presence in key regions for clinical trial execution. The company has over 1,000 employees in China, indicating a substantial operational hub and sourcing of personnel and sites within the country. They are also expanding their 'site navigator program' globally, including in China and Japan, which involves dedicated support to investigator sites in these geographies. Their flagship clinical research unit in Leeds, U.K., is highlighted for its Phase I clinical pharmacology services. The company operates with an integrated global network for its Clinical Pharmacology Services business and has nearly 14,000 employees worldwide.
Sales Geographies And Expansion Plans: Fortrea operates globally, with a presence in over 90 countries. The company has a strong sales footprint across various regions, with particular emphasis on strengthening its position in China, where it has seen strong double-digit growth in its pipeline of opportunities and significant wins. Fortrea is also expanding its 'site navigator program' globally, including in China and Japan, indicating a focus on enhancing its delivery and client engagement in these markets. Their commercial strategy involves better coordination across their global teams.
How Key Themes May Help/Hurt: Fortrea is well-positioned to benefit from the 'MedTech Long '26: CROs' theme, particularly due to the robust biotech funding recovery, which is unlocking R&D budgets for small-to-mid-cap biotech and preclinical services. This directly aligns with Fortrea's strong commercial momentum and net new business weighted towards new and existing biotech clients. The company also benefits from large pharmaceutical companies increasing R&D investment and outsourcing complex, multi-national trials, as large pharma remains a cornerstone of Fortrea's business. Additionally, Fortrea's strategic investments in advanced technologies like its AI-enabled FIT platform align with the theme's emphasis on AI integration enhancing trial efficiency and accelerating drug discovery. However, the company could be hurt by the theme's identified bear points, such as the highly competitive CRO market, which leads to aggressive pricing dynamics, and unfavorable mix shifts, as evidenced by ongoing FSP headwinds and lower pass-through costs impacting revenue. While Fortrea's bookings are strong, sustained industry-wide volatility in net bookings or elevated cancellation rates could pose a risk, although Fortrea's cancellations have remained in line with historical trends.

3 Main Long-Term Bull Details

Sustained Commercial Momentum and Biotech Traction: Fortrea has demonstrated strong commercial execution with a Q2 2026 book-to-bill of 1.06x and a trailing 12-month book-to-bill of 1.12x, marking four consecutive quarters of robust performance. This momentum is significantly driven by increased authorizations and RFPs from the biotech sector, including new-to-Fortrea clients, and strong growth in China, indicating successful market penetration and a healthy demand recovery.
AI-Enabled Operational Differentiation (FIT Platform): The successful launch and ongoing scaling of Fortrea Intelligent Technology (FIT), an AI-enabled integrated platform, is expected to enhance trial speed, predictability, and quality. This strategic investment in AI, alongside strengthened project management and expanded site navigator programs, positions Fortrea for improved win rates, operational efficiency, and long-term differentiation in a competitive market.
Clear Path to Margin Expansion: Fortrea is making solid progress towards its goal of achieving mid-teens adjusted EBITDA margin percentage over the next 3 to 5 years. This is supported by significant cost savings initiatives, disciplined financial management, and an improving mix in its backlog, which is expected to drive substantial profitability improvements as revenue growth accelerates.

3 Main Long-Term Bear Details

Near-Term Revenue Headwinds and Pricing Pressure: Despite underlying full-service clinical revenue growth, Fortrea's Q2 2026 total revenue decreased 4.5% year-over-year, primarily due to lower pass-through costs in both clinical pharmacology and clinical development businesses, as well as continued FSP headwinds. This indicates ongoing competitive and pricing pressures affecting top-line performance and backlog burn.
Uncertainty and Cost of AI Implementation: While Fortrea's AI-enabled FIT platform is promising, management acknowledges it's 'early days,' with efficiency gains expected to outweigh costs only in the 'near to medium term.' The lack of immediate, quantifiable financial benefits from AI and no current changes to commercial pricing models suggest that significant margin improvements from AI are not an immediate catalyst and require substantial ongoing investment.
Dependence on Market Recovery and Execution: Fortrea's improved full-year 2026 revenue guidance still reflects the impact of softer bookings from the first half of 2025, continued FSP headwinds, and lower anticipated pass-through costs. This suggests that while progress is being made, a return to consistent, strong top-line growth is a longer-term prospect, making the company's performance highly dependent on sustained market normalization and flawless execution.

Competitors And Differentiation: Fortrea operates in a very competitive industry. While specific competitor names were not mentioned in the recent earnings call, its peers in the Contract Research Organization (CRO) space include major public companies like IQVIA (IQV), ICON plc (ICLR), Medpace (MEDP), Charles River Laboratories (CRL), and the PPD segment of Thermo Fisher Scientific (TMO), as well as Labcorp (LH) which retains a central laboratory network. Fortrea differentiates itself through its deep scientific and operational capabilities, a patient-inspired mission, and a team focused on execution and accountability. They aim for differentiation through scientific, operational, and therapeutic expertise, consistent execution, and a superior client experience. As one of a small number of truly global CROs, they leverage their scale to manage complex clinical development challenges, emphasizing on-time delivery performance and improving customer satisfaction. A key differentiator is their Fortrea Intelligent Technology (FIT), a clinical trial intelligence ecosystem that integrates data, analytics, machine learning, risk analytics, and AI across the clinical trial life cycle, designed to improve predictability, reduce cost to serve, safeguard quality, and strengthen client partnerships.
Recent Performance & What The Market'S Focused On: Fortrea delivered a solid second quarter in 2026, exceeding expectations. The company reported revenues of $678.2 million, a 4.5% decrease year-over-year, primarily due to lower pass-through costs and FSP headwinds, partially offset by service fee growth in its Clinical Pharmacology business. Adjusted EBITDA for the quarter was $58.7 million, an increase from $54.9 million in the prior year, driven by cost savings initiatives and operational efficiencies. Fortrea achieved a book-to-bill ratio of 1.06x in Q2, marking its fourth consecutive quarter above 1.0x, with trailing 12-month book-to-bill at 1.12x, and net new business of $720.4 million, weighted towards biotech. Backlog stood at $7.8 billion, and cancellations remained in line with historical trends. The company increased its full-year 2026 guidance, now expecting revenue in the range of $2.62 billion to $2.69 billion and adjusted EBITDA in the range of $205 million to $220 million. Operating cash flow was positive $28.9 million, and free cash flow was positive $19.9 million. The market is focused on Fortrea's ability to sustain its strong book-to-bill ratio, particularly with new biotech customers, and translate this into consistent sequential revenue growth. Investors are closely tracking the company's progress towards its mid-teens adjusted EBITDA margin target, driven by cost optimization and an improving study mix, while monitoring the impact and timeline of efficiency gains from its AI-enabled FIT platform. The market is also watching the progression of free cash flow and how the company manages ongoing FSP headwinds and pass-through costs.

Revenue Segments And Estimated Mix: Clinical Services — Mix: Largest segment; Source: Q2 2026 earnings transcript, Ticker_DetailedOverview; Trend: Overall segment revenue decreased 4.5% year-over-year in Q2 2026, primarily due to lower pass-through costs in both clinical pharmacology and clinical development businesses, as well as continued FSP headwinds. This was partially offset by service fee growth in the Clinical Pharmacology business, driven by increased net new business and a more favorable study mix. Clinical Pharmacology Services (CPS) was an area of strength in the quarter.
Enabling Services — Mix: Smaller segment; Source: Ticker_DetailedOverview; Trend: Includes patient access programs and technology solutions; some components (Endpoint Clinical, Fortrea Patient Access) were sold in June 2024, potentially impacting future mix.
Product Brands: Fortrea Intelligent Technology (FIT)
FIT Lifecycle Solutions
FIT Foresight Solutions
FIT Companion Solutions
Xcellerate platform
CRA mobile app

Bull / Bear Details

Fortrea, a pure-play clinical CRO, is demonstrating sustained commercial momentum with a strong book-to-bill and significant biotech traction, reinforced by its

Thesis

Fortrea, a pure-play clinical CRO, is demonstrating sustained commercial momentum with a strong book-to-bill and significant biotech traction, reinforced by its AI-enabled FIT platform. Despite near-term revenue headwinds from FSP and pass-throughs, the company has improved its full-year 2026 guidance and is making solid progress on margin expansion through cost optimization. This positions Fortrea for long-term growth and improved profitability, despite a temporary CFO transition. (Updated: 2026-08-06)

Bull case

Fortrea continues to exhibit strong commercial execution, achieving a Q2 2026 book-to-bill of 1.06x and a trailing 12-month book-to-bill of 1.12x, marking its fourth consecutive quarter above 1.0x. First-half 2026 net new business awards increased 19% year-over-year, driven by robust engagement with new and existing biotech clients and strong performance in Clinical Pharmacology Services.
The company's AI-enabled Fortrea Intelligent Technology (FIT) platform is gaining traction, with its CRA mobile app deployed in over 50 countries and demonstrating early efficiency gains, such as reducing site visit preparation time by nearly 30 minutes. Fortrea is also investing in company-wide AI literacy and equipping employees with Microsoft Copilot, aiming to enhance productivity and client outcomes.
Fortrea has improved its full-year 2026 revenue guidance to $2.62 billion to $2.69 billion and adjusted EBITDA guidance to $205 million to $220 million, reflecting solid first-half performance and confidence in the business. The company expects positive free cash flow for the remainder of 2026 and the full year, supported by continued cost savings and operational efficiencies.

Bear case

Despite underlying service fee growth, Fortrea's Q2 2026 revenue decreased 4.5% year-over-year, primarily due to lower pass-through costs in both Clinical Pharmacology and Clinical Development, as well as ongoing FSP headwinds. While FSP pricing behavior has normalized, the impact of past concessions continues to affect top-line performance and backlog burn.
While Fortrea's AI initiatives are progressing, management acknowledges it is still "too early" to see meaningful differentiation on the commercial side or significant impact on operational metrics. Despite most RFPs now inquiring about AI capabilities, customers are not yet making decisions where AI is the primary factor, suggesting that substantial financial benefits from AI are not an immediate catalyst.
The improved full-year 2026 revenue guidance still implies a year-over-year decline compared to previous periods, indicating that a return to consistent top-line growth remains a 2027 target rather than an immediate prospect. Additionally, the interim CFO appointment due to restrictive covenants with the new CFO's former employer introduces a minor element of leadership transition uncertainty.

Bull / Bear Case

Bear Case: Despite underlying service fee growth, Fortrea's Q2 2026 revenue decreased 4.5% year-over-year, primarily due to lower pass-through costs in both Clinical Pharmacology and Clinical Development, as well as ongoing FSP headwinds. This indicates that past pricing concessions continue to affect top-line performance and backlog burn, making a return to consistent top-line growth a 2027 target rather than an immediate prospect. While Fortrea's AI initiatives are progressing, management acknowledges it is still "too early" to see meaningful commercial differentiation or significant operational impact, suggesting that substantial financial benefits from AI are not an immediate catalyst. Additionally, the interim CFO appointment due to restrictive covenants with the new CFO's former employer introduces a minor element of leadership transition uncertainty.
Bull Case: Fortrea continues to demonstrate strong commercial execution, achieving a Q2 2026 book-to-bill of 1.06x and a trailing 12-month book-to-bill of 1.12x, marking its fourth consecutive quarter above 1.0x. This momentum is significantly driven by robust engagement with new and existing biotech clients and strong performance in Clinical Pharmacology Services, with first-half 2026 net new business awards increasing 19% year-over-year. The company's AI-enabled Fortrea Intelligent Technology (FIT) platform is gaining traction, demonstrating early efficiency gains and positioning Fortrea for long-term operational differentiation. Management has improved its full-year 2026 revenue and adjusted EBITDA guidance, reflecting solid first-half performance and confidence in the business, and expects positive free cash flow for the full year, supported by continued cost savings and operational efficiencies.
More Compelling & Why: Bear. While Fortrea's improved guidance and strong bookings are positive, the persistent year-over-year revenue decline, despite a seemingly reasonable EV/EBITDA of approximately 16.7x, suggests the market is discounting the immediate growth challenges. The stock's significant underperformance post-earnings indicates investor concern over the actual top-line contraction and the 'early days' of AI benefits. My view would flip to Bull if Fortrea demonstrates positive year-over-year revenue growth in the next two quarters, signaling a clear reversal of the top-line headwinds.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
Growth in new-to-Fortrea biotech RFPs and authorizations	Strong engagement and new business wins from biotech clients indicate successful diversification of Fortrea's customer base and its ability to capture growth in a recovering and expanding market segment.	Management commentary on sequential and year-over-year increases in RFPs issued for biotech opportunities, particularly new-to-Fortrea biotech. Also, the proportion of net new business awards weighted towards biotech.	Continued sequential and year-over-year growth in biotech RFPs and authorizations, especially new-to-Fortrea clients = bullish. A decline or stagnation in these metrics = bearish.	Company earnings calls and investor presentations (e.g., Fortrea's Q3 2026 earnings call, expected late October/early November 2026).	PitchBook (for general biotech funding trends); r/biotech subreddit for sentiment.	BioCentury: Biotech funding rounds; EvaluatePharma: Biotech R&D spending trends
Progress towards Fortrea's targeted mid-teens adjusted EBITDA margin percentage	Consistent expansion of adjusted EBITDA margin demonstrates effective cost optimization, operational efficiencies, and a favorable project mix, which are crucial for long-term profitability and shareholder value creation.	Quarterly Adjusted EBITDA and Adjusted EBITDA margin percentage. Monitor for consistent sequential increases and clear progress towards the mid-teens target over the next 3-5 years. Q2 2026 Adjusted EBITDA was $58.7 million.	Consistent sequential improvement in adjusted EBITDA margin and clear articulation of the path to mid-teens = bullish. Stagnation or decline in margin, or revised longer timeline for target = bearish.	Company earnings calls and press releases (e.g., Fortrea's Q3 2026 earnings call, expected late October/early November 2026).	Industry reports on CRO operating margins.	S&P Capital IQ: FTRE Adjusted EBITDA Margin; Refinitiv Eikon: FTRE Adjusted EBITDA Margin
Customer and partner adoption of Fortrea Intelligent Technology (FIT) and its impact on operational metrics	Successful integration and adoption of the AI-enabled FIT platform are critical for enhancing operational efficiency, improving trial predictability, and differentiating Fortrea in a competitive market, driving long-term value.	Management commentary on specific use cases, quantifiable efficiency gains (e.g., reduced site visit preparation time by ~30 minutes per visit), customer feedback, and the scaling of FIT solutions across studies and geographies.	Quantifiable improvements in operational metrics (e.g., reduced trial timelines, improved data quality), positive customer feedback, and increased win rates linked to FIT = bullish. Lack of significant adoption or tangible benefits = bearish.	Company earnings calls, investor presentations, and press releases (e.g., Fortrea's Q3 2026 earnings call, expected late October/early November 2026).	Google Trends: 'Fortrea Intelligent Technology' search volume; Industry news articles on AI in CROs.	Thinknum: Fortrea job postings for AI/Data Science roles (growth indicates investment); SimilarWeb: Fortrea.com web traffic (engagement with tech solutions)
Fortrea's Net Book-to-Bill Ratio	A book-to-bill ratio consistently above 1.0x indicates strong commercial execution and growing demand for Fortrea's services, signaling future revenue growth and market share gains, particularly within the biotech sector.	Quarterly net book-to-bill ratio and trailing 12-month net book-to-bill ratio. Monitor for sustained performance at or above 1.1x. Q2 2026 book-to-bill was 1.06x, and trailing 12-month was 1.12x.	Consistently above 1.1x = bullish, indicating accelerating commercial execution and future revenue growth. Below 1.0x = bearish, signaling contracting demand and potential revenue deceleration.	Company earnings calls and press releases (e.g., Fortrea's Q3 2026 earnings call, expected late October/early November 2026).	Industry analyst reports on CRO bookings trends (e.g., from investment bank research).	Bloomberg Terminal: FTRE Book-to-Bill Ratio; FactSet: FTRE Book-to-Bill Ratio
Achievement of improved full-year 2026 revenue and adjusted EBITDA guidance	Meeting or exceeding the updated full-year guidance demonstrates strong execution against strategic priorities and provides confidence in Fortrea's ability to deliver sustainable growth and profitability, reinforcing investor sentiment.	Full-year 2026 revenue in the range of $2.62 billion to $2.69 billion and adjusted EBITDA in the range of $205 million to $220 million. Monitor Q3 and Q4 results against these targets. Also, watch for continued positive free cash flow.	Affirmation or upward revision of full-year guidance = bullish. Downward revision or missing targets = bearish.	Company earnings calls and press releases (e.g., Fortrea's Q3 2026 earnings call, expected late October/early November 2026).	Analyst consensus estimates for revenue and EBITDA.	Bloomberg Terminal: FTRE Revenue Estimates; FactSet: FTRE EBITDA Estimates

Key Reported Metrics, Reratings Triggers & Results3 rows

This is a key indicator of commercial momentum and future revenue growth, reflecting successful client engagement and diversification, particularly in the biote

Upcoming print · 2026-11-04

Key reported metrics
Metric	Last period	Why it matters
Net New Business Awards	19%	This is a key indicator of commercial momentum and future revenue growth, reflecting successful client engagement and diversification, particularly in the biotech sector. Strong awards build the backlog and drive long-term performance.
Adjusted EBITDA	8.7% (+0.9pp)	This profitability metric is crucial for assessing operational efficiency and progress towards Fortrea's mid-teens margin target. Consistent growth signals effective cost management and an improving project mix.
Total Revenue	$678.2 million (-4.5% y/y growth)	This fundamental metric indicates the company's top-line performance and market demand. Investors watch for a reversal of recent declines and sustained growth, especially given the improved full-year guidance.

Last reported · 2026-07-29

Key reported metrics			Rerating thresholds			Earnings results
Metric	Last period	Why it matters	What's needed for rerating	Rerating context	Earnings date	Actual reported	Hit target?	Notes
Fortrea's Net Book-to-Bill Ratio	12.7%	Achieving a Net Book-to-Bill Ratio of 1.2x or higher signals accelerating demand and strong commercial execution, validating Fortrea's turnaround and AI investments. This boosts investor confidence in future revenue growth and margin expansion, leading to a re-evaluation of its competitive position and a higher valuation multiple, shifting market sentiment to bullish.	Fortrea's Net Book-to-Bill Ratio needs to hit and sustain at or above 1.2x. This would represent a clear acceleration from its Q1 2026 ratio of 1.15x and significantly surpass the established bullish threshold of consistently above 1.1x.	Achieving a Net Book-to-Bill Ratio of 1.2x or higher signals accelerating demand and strong commercial execution, validating Fortrea's turnaround and AI investments. This boosts investor confidence in future revenue growth and margin expansion, leading to a re-evaluation of its competitive position and a higher valuation multiple, shifting market sentiment to bullish.	2026-07-29	1.06x	No	Fortrea reported a book-to-bill ratio of 1.06x for Q2 2026, marking its fourth consecutive quarter above 1.0x. The trailing 12-month book-to-bill was 1.12x. However, the quarterly ratio of 1.06x did not meet the rerating trigger of 1.2x.
Adjusted EBITDA Margin	58.7%	Achieving an Adjusted EBITDA Margin of 8.5% or higher, coupled with an upward revision to full-year guidance, would validate Fortrea's operational turnaround and cost optimization efforts. This signals an accelerated path to its mid-teens margin target, demonstrating improved efficiency, boosting investor confidence, and driving a positive rerating for the stock.	Fortrea Holdings Inc. (FTRE) needs to report an Adjusted EBITDA Margin for Q2 2026 of 8.5% or higher, exceeding its Q1 2026 margin of 7.4% and the implied full-year 2026 guidance range of 7.5% to 8.3%. Additionally, an upward revision of the full-year 2026 Adjusted EBITDA guidance, implying a margin consistently above 8.5-9% (aligning with some analyst projections of 8.6% for 2026), would further signal a stronger rerating.	Achieving an Adjusted EBITDA Margin of 8.5% or higher, coupled with an upward revision to full-year guidance, would validate Fortrea's operational turnaround and cost optimization efforts. This signals an accelerated path to its mid-teens margin target, demonstrating improved efficiency, boosting investor confidence, and driving a positive rerating for the stock.	2026-07-29	8.7% (+0.9pp)	Yes	Fortrea's Adjusted EBITDA for Q2 2026 was $58.7 million on revenues of $678.2 million, resulting in an Adjusted EBITDA Margin of approximately 8.7%. This exceeded the rerating trigger of 8.5%. Furthermore, the company increased its full-year 2026 Adjusted EBITDA guidance to a range of $205 million to $220 million, which is an upward revision from the previous guidance. This indicates strong progress on cost optimization and operational efficiencies.
Total Revenue	-2.3%	Achieving positive year-over-year revenue growth and raising full-year guidance above current analyst expectations would validate Fortrea's turnaround story and strong book-to-bill ratio. This signals successful commercial execution and market penetration, differentiating FTRE from peers and confirming a path to sustainable top-line expansion and improved profitability.	Fortrea needs to report Q2 2026 Total Revenue that demonstrates positive year-over-year growth, reversing the 2.3% decline seen in Q1 2026. For a sustained rerating, the company would also need to revise its full-year 2026 revenue guidance upwards to exceed $2.72 billion, signaling a return to positive year-over-year growth. The current full-year 2026 revenue guidance is $2.55 billion to $2.65 billion, which has been reaffirmed. Analyst consensus for Q2 2026 revenue is $647.57 million.	Achieving positive year-over-year revenue growth and raising full-year guidance above current analyst expectations would validate Fortrea's turnaround story and strong book-to-bill ratio. This signals successful commercial execution and market penetration, differentiating FTRE from peers and confirming a path to sustainable top-line expansion and improved profitability.	2026-07-29	$678.2 million (-4.5% y/y growth)	No	Q2 2026 revenue was $678.2 million, representing a 4.5% decrease year-over-year, primarily due to lower pass-through costs and continued FSP headwinds. This did not meet the rerating trigger of achieving positive year-over-year growth. While the company did increase its full-year 2026 revenue guidance to $2.62 billion to $2.69 billion, the upper end of this revised guidance did not exceed the rerating threshold of $2.72 billion.

Key Questions

Can Fortrea translate its sustained strong book-to-bill and improved full-year guidance into sequential revenue growth in the second half of 2026, effectively o

Can Fortrea translate its sustained strong book-to-bill and improved full-year guidance into sequential revenue growth in the second half of 2026, effectively offsetting continued FSP headwinds and lower pass-through costs?

Question 2: Will Fortrea's cost optimization initiatives and improving project mix continue to drive adjusted EBITDA margin expansion at a consistent pace in the second half of 2026, demonstrating clear progress towards its mid-teens target?
Question 3: Will Fortrea's AI-enabled FIT platform begin to demonstrate more widespread and quantifiable operational efficiencies or contribute to competitive differentiation in commercial wins over the next quarter, given management's 'early days' assessment?

Earnings Transcript Summary2 rows

2026-07-29 · 2026Q2 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Commercial Excellence: Management is focused on building commercial momentum, expanding customer relationships (reach), demonstrating differentiated expertise (relevance), and earning repeat business through consistent execution. This is evidenced by a book-to-bill of 1.06x and strong net new business wins, particularly in biotech. 2. Operational Excellence: The company is committed to strengthening operational delivery by focusing on project management, site activation, enrollment performance, and quality. They are also embedding Fortrea Intelligent Technology (FIT), an AI-enabled platform, across workflows to improve predictability, reduce cost to serve, and safeguard quality. 3. Financial Discipline: Management is focused on driving growth and margin expansion through financial rigor, cost management, and targeted investments. They aim to achieve improved full-year revenue and adjusted EBITDA guidance, while also strengthening the balance sheet and continuing to delever.	Call Takeaway & ToneThe overall takeaway of the call was that Fortrea is making steady and continued progress on its strategic transformation, demonstrating improved commercial momentum, strengthening operational delivery, and maintaining financial discipline. The tone was cautiously optimistic and confident, with management highlighting strong book-to-bill ratios, particularly in biotech, and the ongoing integration of AI-enabled capabilities as key drivers for future growth and margin expansion. The company also addressed the interim CFO transition, assuring continuity in financial leadership.	Prior Quarter'S Y/Y Growth By SegmentIn Q1 2026, total revenue decreased 2.3% year-over-year (-3.2% constant currency). Underlying full-service clinical revenue grew year-over-year (specific percentage not provided). Both Clinical Pharmacology and Clinical Development businesses were impacted by lower pass-through costs, and FSP continued to be a headwind.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Margin Progression and FSP/Pass-Through Impact: Analysts inquired about the contributors to margin improvement and the duration of FSP drag. Management responded that margin improvement is driven by rightsizing the organization (cost savings), higher-margin projects burning off into revenue, and continued operational discipline in both global clinical development and clinical pharmacology groups. 2. Commercial Momentum, Bookings, and Competitive Environment: Analysts questioned the seasonality of bookings and changes in the competitive landscape. Management stated that the strong Q2 bookings were due to deliberate actions taken to strengthen the commercial team and diversify the client base, rather than seasonality. They noted an improving market, but a consistently competitive industry, with a return to more rational pricing behavior compared to previous 'irrational' FSP pricing. 3. AI Strategy and its Tangible Benefits: Analysts asked about the impact of Fortrea's AI strategy on proposal activity, win rates, and whether clients are prioritizing AI capabilities. Management acknowledged that while most RFPs now ask about AI capabilities, it is still too early to see meaningful differentiation on the commercial side or significant impact on operational metrics. They emphasized a deliberate, integrated approach to AI adoption across all functions, aiming for long-term productivity and insight enhancement.	Revenue SegmentsTotal revenue decreased 4.5% year-over-year to $678.2 million. This was primarily due to lower pass-through costs in both the Clinical Pharmacology and Clinical Development businesses, as well as continued FSP headwinds. These decreases were partially offset by service fee growth in the Clinical Pharmacology business, driven by increased net new business and a more favorable study mix.

2026-05-05 · 2026Q1 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Commercial Excellence and Growth: Management is intensely focused on improving commercial momentum, evidenced by the strong book-to-bill of 1.15x and a trailing 12-month book-to-bill of 1.05x. They are particularly emphasizing diversifying the customer base, with notable success in biotech, and strengthening their presence in China. This is driven by their "3 Rs" framework: reach, relevance, and repeat. 2. Operational Excellence and Technology Enablement (FIT Platform): A major focus is on delivering quality, predictability, and efficiency for clients at scale, with the recent launch of Fortrea Intelligent Technology (FIT) being a significant step. FIT is an AI-enabled integrated platform designed to improve predictability, reduce cost to serve, improve quality, and strengthen client partnerships. Management sees AI as a "force multiplier" to aid judgment, not replace it, and expects it to increasingly support win rates, operational efficiency, and longer-term differentiation. 3. Financial Excellence and Margin Expansion: Management is committed to driving margin expansion, disciplined cash management, and strengthening the balance sheet. They are making solid progress on cost savings initiatives, delivering nearly $16 million gross and over $9 million net in Q1 2026, and are on a journey toward mid-teens adjusted EBITDA margin percentage over the next 3 to 5 years.	Call Takeaway & ToneThe overall takeaway of the call is that Fortrea is making solid progress on its strategic transformation journey, demonstrating improved commercial momentum and operational discipline. The tone was cautiously optimistic and confident. Management highlighted strong book-to-bill ratios driven by biotech engagement and the successful launch of its AI-enabled FIT platform as key differentiators. While acknowledging near-term revenue headwinds from lower pass-throughs and FSP contracts, the company is on track with cost optimization initiatives and reiterated its full-year guidance, signaling confidence in its path to growth and margin expansion.	Prior Quarter'S Y/Y Growth By SegmentTotal Revenue (Q4 2025): -5.2% Y/Y. Clinical Pharmacology (Q4 2025): grew (specific percentage not provided, but contributed to full-year 2025 revenue increase). FSP (Q4 2025): reduced (specific percentage not provided, but was a headwind for Q4 2025 and offset full-year 2025 revenue increase).	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Biotech Market Backdrop and Share Gains: Analysts inquired about the encouraging book-to-bill performance, specifically asking if the improvement in small biotech was due to market recovery or Fortrea gaining market share. Management Response: Anshul Thakral stated that they are seeing a "speedier path to recovery" in biotech, with RFPs up sequentially, particularly for new-to-Fortrea biotech. He expressed pride in the commercial team's execution, noting that win rates are consistent, and the "aperture is increasing," bringing more new biotech clients into their pipeline. He acknowledged that share gain is hard to quantify due to private competitors but emphasized the uptick in activity and conversations. 2. AI Impact on Costs, Efficiencies, and Pricing Models: Analysts questioned when efficiency gains from AI would outweigh implementation costs and if AI would lead to changes in pricing models. Management Response: Anshul reiterated that it's "early days" for AI. He noted that most sponsor conversations are constructive, focusing on collaborative problem-solving rather than immediate commercial model changes. He expects initial costs for infrastructure and pilots, but believes that in the "near to medium term," efficiency gains will start to outweigh these costs. He sees AI as a long-term tailwind for the industry, leading to faster clinical trials and more drug development, ultimately benefiting CROs. 3. Margin Progression and Investments: Analysts sought clarity on the cadence of margin improvement, especially in the second half of 2026, and the nature of planned investments. Management Response: Jill McConnell indicated a "slow gradual increase" in margins over the year, with a modest sequential step-up in Q2. She explained that investments are targeted towards compensating employees in line with market, merit increases, and relatively smaller organic investments in areas like therapeutic expertise and the commercial organization to accelerate future growth. She confirmed that the FSP rate card impact is already embedded in Q1 and guidance.	Revenue SegmentsTotal Revenue: -2.3% Y/Y (-3.2% constant currency). Underlying full-service clinical revenue: grew year-over-year (specific percentage not provided). Clinical pharmacology and clinical development businesses: lower pass-through costs (no specific growth rate given for the segments themselves, only the impact of pass-throughs). FSP: headwinds (no specific growth rate given).

Transcript Tidbits2 rows

2026-07-29

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketFortrea is seeing encouraging growth with new and existing biotech clients and is expanding the aperture of its customer relationships to bring more opportunities into its pipeline. The Clinical Pharmacology Services (CPS) business continues to benefit from strong scientific capabilities, an integrated global network, and increasing customer demand. The company noted strong contributions from new-to-Fortrea biotech customers, which is broadening and diversifying its pipeline. Fortrea also continues to see growth in China, particularly from Chinese biotechs and U.S. companies partnering with them for global studies.	About CompetitionThe industry remains very competitive across all sectors and product categories. Management noted that the 'temporal irrational behavior' seen in pricing for Functional Service Provider (FSP) contracts in the past has subsided, and 2026 has seen a return to a normal environment with rational pricing behavior from both competitors and clients. Despite this, it remains a competitive environment where companies are actively pursuing growth.	About The Broader IndustryThe broader demand backdrop has continued to improve, with more constructive customer engagement from both pharmaceutical and biotech companies. Biotech funding has continued to strengthen, and large pharma procurement processes are more normalized. The market environment has become more supportive, though Fortrea's results are attributed to deliberate actions rather than just market recovery. Oncology remains the strongest therapeutic area in the market.	Where Things Are HeadedFortrea has improved its full-year 2026 revenue and adjusted EBITDA guidance, now expecting revenue in the range of $2.62 billion to $2.69 billion and adjusted EBITDA between $205 million and $220 million. The company anticipates that the next phase of margin expansion will be driven by growth, mix improvement, and operating leverage. Fortrea expects to be free cash flow positive for the remainder of 2026 and for the full year. Management is encouraged by the business as it enters the second half of 2026, focusing on executing its clear strategy, operating with greater discipline, and building momentum across commercial, operational, and financial priorities. They expect relatively stable and flat performance in the second half of the year.	Updates On ThemeCROs:	Broader Themes EmergingArtificial Intelligence (AI) Integration and Literacy: Fortrea is actively integrating AI through its FIT platform and equipping its nearly 14,000 employees with Microsoft Copilot. The company has also launched a comprehensive company-wide AI literacy program. This approach emphasizes AI as a 'force multiplier' to enhance human judgment and productivity across all functions, rather than replacing roles, indicating a broader industry trend towards upskilling the workforce for an AI-enabled era.	Bullish-Leaning Quotes (Short)We are pleased to report another quarter of steady progress on that journey, improving our full year revenue and adjusted EBITDA guidance. Our book-to-bill was 1.06x, representing our fourth consecutive quarter above 1.0x. First half 2026 net new business awards increased 19% year-over-year. The environment has become more supportive, but our results are not simply the result of market recovery. Our on-time delivery performance has remained a key differentiator. Customer satisfaction trajectory has continued to improve. We continue to expect positive free cash flow for the remainder of 2026 and for the full year.	Bearish-Leaning Quotes (Short)Our new CFO, Jason Madlock, is not currently able to act as a CFO for Fortrea due to an ongoing proceeding relating to restrictive covenants with his former employer. Second quarter revenue was $678.2 million, a 4.5% decrease year-over-year due primarily to lower pass-through costs in both our clinical pharmacology and clinical development businesses as well as continued FSP headwinds. While book-to-bill can vary from quarter-to-quarter, the broader trend of elevated bookings gives me continued confidence that our commercial execution is improving. While there is still work to do, we are executing against a clear strategy.	HiringDirect costs in the quarter decreased primarily due to lower headcount-related personnel costs. SG&A also decreased due to lower headcount-related personnel costs. Fortrea has equipped its nearly 14,000 employees with Microsoft Copilot on their desktop and launched a comprehensive company-wide AI literacy program. These investments are explicitly stated as 'not about replacing people' but rather about 'giving our teams better tools' to enhance speed, consistency, and insight, and to enable employees to develop their careers in an AI era.

2026-05-05

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketFortrea diversified its customer base with notable success in biotech, seeing a significant year-over-year improvement in authorizations skewed towards this sector. The number of RFPs issued for biotech opportunities increased both sequentially and year-over-year, including new-to-Fortrea biotech clients. The company also saw strong double-digit growth in its pipeline of opportunities and significant wins in China. Fortrea achieved its best first quarter since its founding for authorizations in clinical pharmacology, supported by both new and repeat customers, and successfully performed its first-in-human dosing in patients with immune thrombocytopenia at its Leeds clinic, expanding into rare blood disorder studies. The site navigator program was broadened globally, including expansion in China and Japan.	About CompetitionManagement noted that share gain is a difficult question to answer due to the lack of perfect visibility on competitor data, especially with many private competitors. Fortrea is being invited to certain large and mid-sized pharma renewals that it wasn't invited to in the past, indicating improved competitive positioning. While there's always chatter and 'counter-detailing' around 'rescue wins' when competitors face difficulties, management stated there was no significant trend line of rescues happening in Q1.	About The Broader IndustryThe market environment is gradually becoming more favorable and continues to stabilize with early signs of improvement. Large pharma is more constructive, and biotech funding has inflected positively versus last year, supporting a steadier demand backdrop. Clinical trial starts rebounded this quarter. Across the industry, despite more data, tools, and AI pilots, there hasn't been a commensurate increase in drug approvals. The CRO industry is seen as ready for the 'AI revolution,' similar to how it adapted during the pandemic. The regulatory landscape is shifting to embrace and accelerate innovation for patient outcomes.	Where Things Are HeadedFortrea remains on track with its plans for growth and margin expansion, aiming for mid-teens adjusted EBITDA margin percentage over the next 3 to 5 years. The company reiterated its full-year 2026 revenue guidance of $2.55 billion to $2.65 billion and adjusted EBITDA guidance of $190 million to $220 million. For Q2, a modest sequential increase in revenue is anticipated, driven by higher underlying service fee revenue and pass-through costs, with a slight step-up in adjusted EBITDA. Management plans an Investor Day in the second half of the year to detail margin progression. Longer-term, AI is viewed as a net positive tailwind for the industry, potentially leading to modestly faster clinical trials and more drug development.	Updates On ThemeFortrea,	Broader Themes EmergingArtificial Intelligence (AI) is a significant emerging theme, with Fortrea launching its 'Fortrea Intelligent Technology' (FIT) platform, which integrates persona-driven AI-powered solutions. The company emphasizes that AI's goal is not just automation but to create a 'force multiplier' by aiding judgment in critical decisions within clinical trials. Discussions with sponsors are constructive, focusing on collaborative problem-solving rather than immediate commercial model changes, as it is still 'early days' for widespread AI solutions.	Bullish-Leaning Quotes (Short)We started the year strong in the first quarter and remain on track with our plans. We had a Q1 book-to-bill of 1.15x and a trailing 12-month book-to-bill of 1.05x, reflecting improved commercial execution for the third consecutive quarter. Biotech funding has inflected positively versus last year, supporting a steadier demand backdrop. The launch was met with strong reactions from customers, partners and investors. We reiterate our targeted full year 2026 revenue guidance in the range of $2.55 billion to $2.65 billion, and targeted adjusted EBITDA guidance in the range of $190 million to $220 million. Longer term, I do see this as a net-net tailwind for the industry overall.	Bearish-Leaning Quotes (Short)First quarter revenue was $636.5 million, down 2.3% year-over-year. The decline was driven primarily by lower pass-through costs... as well as continued FSP headwinds. If we don't redesign how decisions are made, AI will amplify noise rather than improve outcomes. Backlog burn of 8.2% in the first quarter was lower sequentially, driven primarily by the impact of previously communicated pricing concessions on a large pharma FSP contract. It's harder to determine what will happen in the nearer term because it's harder to see the impact given all of the... not a lot of progress just yet.	HiringDirect costs in the quarter decreased due to lower headcount-related personnel costs, while SG&A also saw a decrease primarily from lower headcount-related personnel costs. These reductions were achieved despite a year-over-year increase in variable compensation expense. The company made 'continued investments in our people' and 'targeted investments in our employees' for things like merit, aiming to compensate employees in line with a 'market that's starting to get just a touch more competitive.' Fortrea plans to 'add back personnel but in a more measured way' as it grows and continues to look for talented colleagues and individuals at all levels to bring into the organization as it returns to growth.